NC's $230M Biomanufacturing Training Investment: Doubling Down On Workforce Development

By Bill Bullock, NC Biotech

North Carolina is rapidly scaling its biomanufacturing workforce to match one of the most significant waves of pharmaceutical investment in its history. With more than $230 million flowing into community college training infrastructure, the state is reinforcing a long-standing, collaborative model that connects education, industry, and economic development. These investments arrive as $24.5 billion in life sciences expansion—spanning companies like Amgen, Novo Nordisk, and Eli Lilly—drives demand for highly skilled talent. From legacy programs like BioWork to next-generation facilities equipped for AI, automation, and advanced bioprocessing, North Carolina is evolving its training ecosystem to meet the realities of modern manufacturing.

Learn more about a pipeline that is designed not just to fill jobs, but to sustain innovation, accelerate production, and strengthen the region’s global competitiveness in delivering life-changing therapies.